FDA Biologics Center Performance To Be Reviewed By Advisory Committees
This article was originally published in The Pink Sheet Daily
Executive Summary
Center for Biologics Evaluation & Research expects the review to take place within the year. CDER Office of Drug Evaluation VI's continued use of CBER facilities will likely be part of that review.